Shaniqua J. Anum, Julie Kanter/ scholars.uab.edu
Aug 23, 2026, 14:10
Intravenous Arginine Fails to Reduce Acute Sickle Cell Pain – JAMA
JAMA shared a post on LinkedIn about a recent article by Shaniqua J. Anum and Julie Kanter, adding:
”Acute pain episodes in Sickle Cell Disease remain a leading cause of emergency department visits and hospitalization, yet treatment still relies largely on opioids, nonsteroidal anti-inflammatory drugs, and intravenous fluids.
The STArT trial of intravenous Arginine found no overall benefit vs placebo, and heterogeneity in acute pain mechanisms and trial end points may have limited detection of a vascular-targeted treatment effect.”
Title: Arginine Treatment and Sickle Cell Disease Pain — A Great STArT, but a Hard End Point
Authors: Shaniqua J. Anum, Julie Kanter
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 23, 2026, 15:23Katerina Pavenski: What’s New in the 2025 AABB and ICTMG Guidelines?
-
Aug 23, 2026, 15:14Denis Nikolov: A Call for Routine UACR Assessment in High-Risk Cardiovascular Patients
-
Aug 23, 2026, 15:1310 Posts Not to Miss This Week
-
Aug 23, 2026, 14:52Alejandro González Veliz: How Plaque Morphology Shapes PCI Outcomes
-
Aug 23, 2026, 14:16Vikram Sinai Talaulikar: Age-Dependent Long-Term Outcomes of Postmenopausal Hormone Replacement Therapy
-
Aug 23, 2026, 14:00Mohd Ashhad: What Should Be Done Immediately When a Blood Transfusion Reaction Occurs?
-
Aug 23, 2026, 13:56Strengthening Haemophilia Care Through National Guidelines in Kenya – Kenya Haemophilia Association
-
Aug 23, 2026, 13:52Tarek Kammoun: Case of the Day – Superior Vena Cava Thrombectomy
-
Aug 23, 2026, 13:50Ali Rafat: Targeting the Inflammatory Engine of Myeloproliferative Neoplasms